

Hong Kong Stock Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



開拓藥業有限公司*

KINTOR PHARMACEUTICAL LIMITED

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 9939)

**VOLUNTARY ANNOUNCEMENT
DOSING OF FIRST FEMALE PATIENT IN PHASE II
CLINICAL TRIAL OF KX-826 IN CHINA**

This is a voluntary announcement made by Kintor Pharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) to update its shareholders and potential investors on the latest business advancement of the Group.

The board (the “**Board**”) of directors (the “**Directors**”) is pleased to announce that the Company has dosed the first patient in its phase II clinical trial (the “**Phase II Clinical Trial**”) of pyrilitamide (“**KX-826**”), a potential first-in-class topical drug developed by the Group, in China for the treatment of androgenetic alopecia (“**AGA**”) female patients.

The Phase II Clinical Trial is a randomized, double-blind, placebo-controlled, multi-regional study to evaluate the efficacy and safety of KX-826 for the treatment of female AGA adults (N=160). The primary endpoint for the trial is the change from baseline in non-vellus target area hair counts (TAHC) at week 24.

KX-826 is an androgen receptor (AR) antagonist and a potential first-in-class topical drug for the treatment of AGA and acne vulgaris. For the AGA indication, on 8 September 2021, the Company announced that the primary endpoint of the phase II clinical trial of KX-826 on male AGA adults was met, as results showed good efficacy and safety profile. On 11 July 2021, the Company announced that the Food and Drug Administration of the United States had greenlighted KX-826’s phase II clinical trial for AGA to be conducted in the United States. For the acne vulgaris indication, the phase I clinical trial of KX-826 has been completed, and the Company is preparing for phase II clinical trial in China. Please refer to the announcements of the Company dated 8 September 2021 and 11 July 2021, respectively, for details.

Warning under Rule 18A.08(3) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: There is no assurance that pyrilitamide will ultimately be successfully developed and marketed by the Company. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
KINTOR PHARMACEUTICAL LIMITED
Dr. Youzhi Tong
Chairman, Executive Director and Chief Executive Officer

Hong Kong, 12 November 2021

As of the date of this announcement, the executive Director is Dr. Youzhi Tong; the non-executive Directors are Mr. Gang Lu, Mr. Weipeng Gao, Dr. Yan Wang, Mr. Wei Zhang and Ms. Geqi Wei; and the independent non-executive Directors are Dr. Michael Min Xu, Mr. Wallace Wai Yim Yeung and Prof. Liang Tong.

* *For identification purpose only*